Promising early results from a target discovery collaboration with Gilead Sciences, Inc. are yielding multiple windfalls for Tango Therapeutics, Inc. – Gilead is increasing the size and scope of the original collaboration inked in 2018, it is making a $20m equity investment in Tango, and that is prompting Tango’s existing series B backers to purchase further equity to maintain their ownership proportion in the biotech.
All told, Tango gets $125m up front from Gilead in addition to the $20m investment, the partners announced 17 August....








